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Abstract 
 
Parkinson’s disease is a very common neurodegenerative disorder. Patients usually 
undergo destruction of substantia nigra to develop typical symptoms such as resting 
tremor, hypokinesia, and rigidity. However, the exact mechanism of Parkinson’s 
disease is still unknown, so it is called idiopathic Parkinsonism. According to my 
microarray analysis of peripheral blood leukocytes and substantia nigra brain tissue, I 
propose that Parkinson’s disease is actually a TH17 dominant autoimmune disease. 
Based on the microarray data in substantia nigra, HSP40, HSP70, HSP90, HSP27, 
HSP105, TLR5, TLR7, CEBPB, CEBPG, FOS, and caspase1 are significantly up-regulated. 
In peripheral leukocytes, NFKB1A, CEBPD, FOS, retinoic receptor alpha, suppressor of 
IKK epsilon, S100A11, G-CSF, MMP9, IL-1 receptor, IL-8 receptor, TNF receptor, 
caspase8, c1q receptor, cathepsin Z, HLA-G, complement receptor1, and complement 
5a receptor. General immune related genes are also up-regulated including ILF2, 
CD22, CD3E, BLNK, ILF3, TCR alpha, TCR zeta, TCR delta, LAT, ITK, Ly9, and BANK1. The 
autoantigen is mainly alpha-synuclein. After knowing the exact disease 
pathophysiology, we can develop better drugs to prevent or control the detrimental 
disorder.  
 
Introduction 
 
Parkinson’s disease is the second most common neurodegenerative disorder. Primary 
Parkisonism is also called idiopathic Parkinson’s disease because its exact etiology is 
still unknown. After the destruction of substantia nigra of midbrain, patients will 
develop resting tremor, cogwheel rigidity, hypokinesia, and postural instability. 
Patients’ life expectancy is much shorter than normal healthy population. Even it is a 
very common and detrimental illness, the etiology and pathogenesis is still a puzzle. 
By using microarray analysis of peripheral blood leukocytes and substantia nigra 
brain tissue, I find out that idiopathic Parkinsonism is actually a TH17 dominant 
autoimmune disease. Summary of all previous literatures also support that 
Parkinson’s disease is a TH17 autoimmune illness.  
 
Materials and methods 
 
Microarray datasets of Parkinson’s disease 
 
In this paper, I incooperate two microarray datasets for analysis. The fist one is 
peripheral blood mononuclear cell gene expression profiles in Parkinson’s disease 
patient. The dataset GSE6613 is available in GEO website. Dr. C.R. Scherzer published 
the research results of peripheral blood biomarkers for Parkinson’s disease in PNAS. 
The second dataset(GSE7621) is substantia nigra gene expression profiles in 
Parkinson’s disease. Substantia nigra is the major affected brain area of Parkinson’s 
disease. 
 
Statistical analysis 
 
RMA express software(UC Berkeley, Board Institute) is used to do normalization and 
to rule out the outliners of the above dataset. I rule out the potential outliners of 
samples due to the following criteria:  
1. Remove samples which have strong deviation in NUSE plot 
2. Remove samples which have broad spectrum in RLE value plot 
3. Remove samples which have strong deviation in RLE-NUSE mutiplot 
4. Remove samples which exceed 99% line in RLE-NUSE T2 plot 
After the analysis of RMA express, we select 47 Parkinson’s disease and 19 healthy 
controls. We remove GSE153479, GSE153497, and GSE153508 in healthy control due 
to RNA express analysis. We remove GSE153411, GSE153421, GSE153454 in 
Parkinsonism group. (Figure 1 and Figure 2) Then, we use Genespring to find out 
statistically significant expressed genes in substantia nigra and peripheral leukocytes 
of Parkinson’s disease. 
 
Validation by RT-PCR 
 
Since this study is a secondary dataset analysis, I don’t have samples in hand to do 
wet bench validation such as RT-PCR. However, in Dr. Scherzer’s paper, he performed 
RT-PCR to confirm his result of microarray experiment by using RT-PCR. He found 
that the gene ST13, a HSP70 cofactor, is down-regulated in Parkinsonism compared 
to that in Healthy control due to microarray analysis. Then, he used quantitative 
real-time PCR assays based on precise fluorogenic 5’ nuclease chemistry in a large set 
of 39 Parkinsonism patients and 12 age-, sex-, and blood count- matched healthy 
controls. He used the housekeeping gene glyceraldehydes-3-phosphate 
dehydrogenase to control for input RNA and the comparative threshold cycle method 
for analysis. The RT-PCR results confirmed that ST13 is lower in Parkinsonism patients. 
Thus, it states that the microarray platform of Dr. Scherzer’s experiments is valid and 
reliable. 
 
Results 
 Heat shock protein, Toll-like receptor, Caspases, and TH17 related gene up-regulation 
in substantia nigra of Parkinson’s disease patients 
 
In the first dataset, we selected 816 genes of substantia nigra of Parkinson’s disease 
compared to healthy control with fold change>1.5 and Benjamin adjusted false 
discovery rate<0.05. Then, we selected immune-related genes from this 816 
genelist.(Table1) We find out that heat shock protein genes are almost all 
up-regulated in Parkinson’s disease including HSP40, HSP70, HSP90, HSP27, and 
HSP105. In addition, TLR5 and TLR7 are up-regulated as well. Based on several 
references, TLR5 and TLR7 can recognize heat shock protein to trigger TH17 immunity. 
Several toll-like signaling molecules are also up-regulated in Parkinson’s disease. In 
addition, many TH17 related transcription factors are up-regulated in Parkinson’s 
disease including CEBPbeta, CEBPgamma, and FOS(AP1). STAT1, the key transcription 
factor for TH1 and TH9 immunity, is downregulated in Parkinson’s disease patients. 
Key TH17 cytokine receptors are also up-regulated including IL-17 receptor and TGF 
beta receptor. And, TH2 cytokine receptor-IL13 receptor is down-regulated in 
Parkinson’s disease substantia nigra. Finally, the key downstream effector molecule 
caspase1 of TH17 cytokine IL-1 is up-regulated in Parkinson’s patients. This caspase 1 
up-regulation may closely related to the neuron death triggered by TH17 cytokine 
IL-1. 
 
TH17 related molecules are up-regulated in peripheral leukocytes of Parkinson’s 
disease patients 
 
In our second analysis, we find out that 505 significantly expressed genes in 
peripheral leukocytes of Parkinson’s patients with fold change>1.1 and unadjusted 
false discovery rate P<0.05. Then, we pick 103 immune related genes out of the 505 
genelist. (Table2) We find out that many Th17 related molecules are up-regulated in 
WBC of Parkinson’s disease patients. 
 
First of all, many TH17 driven transcription factors are up-regulated in leukocytes of 
Parkinsonism patients. NFKB1A, CEBPD, FOS(AP-1), retinoic receptor alpha, and 
suppressor of IKK epsilon are up-regulated. They are master transcription factors for 
TH17 immunity. Retinoic receptor alpha is related to the differentiation of main TH17 
effector cells-Neutrophils. Besides, the TH9 (THαβ) related transcription factor IRF8 is 
down-regulated.  
 
Second, many TH17 effector molecules are also up-regulated in peripheral leukocytes 
of Parkinson’s disease. S100A11, LPS induced TNF factor, TNF alpha induced protein2, 
CD32, G-CSF, lysosomal mannosidase, MMP9, CD16b, type II interleukin 1 receptor, 
interleukin 8 receptor alpha & beta, TNF receptor 9 & 1A & 10C, TNF factor 14, 
casapase8, S100A11P, CD93 (c1q receptor), cathepsin Z, HLA-G, leukocyte 
immunoglobulin-like receptors, type1 thrombospondin containing 7A, complement 
receptor1, IgG Fc receptor transporter alpha, and complement 5a receptor are all 
up-regulated after Parkinson’s disease. These up-regulated molecules highly suggest 
that TH17 immunological pathway is triggered in Parkinsonism. In addition, Fas 
inhibitory gene and BCL2 are down-regulated that suggest apoptotic signals are 
up-regulated in Parkinson’s disease. 
 
Lymphocyte related genes and immune genes other than TH17 pathway are 
down-regulated in leukocytes of Parkinson’s disease. Generally, neutrophils are 
up-regulated and lymphocytes are down-regulated in TH17 immunity. Thus, this 
result can also help to point out Parkinson’s disease is a TH17 dominant autoimmune 
disease. These lymphocyte related genes include ILF2, CD22, CD3E, BLNK, ILF3, TCR 
alpha, TCR zeta, LAT, ITK, LY9, BANK1, and TCR delta. TH1, TH9, and TH2 immune 
genes are down-regulated including GBP1, IRF8, CD44, KIR3DL2, HEBP1, HEBP2, and 
TRAF3. IL-32 which can suppress NFkB and STAT3(TH17 transcription factor) is also 
down-regulated in leukocytes of Parkinson’s disease.  
 
Unlike the up-regulation of heat shock proteins in substantia nigra, heat shock 
protein genes in peripheral leukocytes are down-regulated in Parkinson’s disease 
patients. These heat shock protein related genes include HSP90AB1 and ST13. In 
addition, the main autoantigen of Parkinsonism-alpha synuclein gene is 
down-regulated in leukocytes of Parkinson’s disease patients as well. There might be 
some negative feedback machinery for these down-regulated disease related genes.    
 
Discussion 
 
Idiopathic Parkinson’s disease is a very common neurodegenerative disorder, but its 
etiology is still unknown. Although there are a few cases of familial Parkinson’s 
diseases, sporadic Parkinson’s diseases are still the major population of this disorder. 
Parkinson’s disease is found to be associated with several risk factors such as MPTP 
exposure, heavy metal such as Manganese exposure, pesticides such as rotenone or 
paraquet exposure, herbicides such as Agent Orange exposure, and Influenza virus 
infection.(Betarbet, Sherer et al. 2000) Estrogen, anti-oxidants, caffeine, and NSAID 
have protective roles from Parkinson’s disease.(Ross, Abbott et al. 2000; Chen, Zhang 
et al. 2003; Sawada and Shimohama 2003) Here, I propose that Parkinson’s disease is 
actually a TH17 dominant autoimmune disease which can explain the above 
evidences.  
 
Alpha synuclein is the major accumulated protein forming inclusion bodies in 
substantia nigra neurons of Parkinson’s patients. In familial Parkinsonism, 
autoantibody against mutation of alpha synuclein can contribute to the disease 
pathogenesis.(Papachroni, Ninkina et al. 2007) Alpha synuclein is a kind of acute 
response amyloid protein which can be up-regulated by Th17 cytokine IL-1 during 
some bacterial infection.(Griffin, Liu et al. 2006) Similar to other neurodegenerative 
diseases such as Alzheimer’s disease, the accumulation of alpha synuclein can 
up-regulate molecular chaperons such as heat shock protein 60 or heat shock protein 
70 to trigger toll-like receptor driven TH17 immunity. Heat shock proteins released by 
neuron or glia cells can activate TLR2/4/5/7 of immune cells to trigger TH17 
cytokines or chemokines.(Asea, Kraeft et al. 2000) Neuron or glia cells can also posse 
Toll-like receptor to trigger TH17 cytokine such as IL-6 or TNF alpha release in neuron 
or glia cells.(Alvarez-Erviti, Couch et al. 2011) These cytokines can be autocrine to 
enhance more Th17 cytokine release. More immune effector cells will be recruited 
and release more TH17 cytokines and chemokines. TH17 cytokine IL-1 can in turns 
up-regulate more alpha synuclein in neuron or glia. That is a vicious cycle. In addition, 
TH17 cytokines such as IL-1, TNFα, and IL-6 can act on neuron cells to undergo 
Wallerian-like degeneration.(Saha and Pahan 2003) That is the pathophysiology of 
Parkinson’s disease. This pathogenesis is very similar to other neurodegenerative 
disorders such as Alzheimer’s disease and Huntington’s disease. 
 
Witebsky’s postulates are the standard criteria to decide if a disorder is an 
autoimmune disease. There are three requirements in Witebsky’s postulates: 1. 
Direct evidence from transfer of pathogenic antibody or T cells 2. Indirect evidence 
based on reproduction of the autoimmune disease in experimental animal 3. 
Circumstantial evidence from clinical clues. First, in an Acta Neurology paper, 
injection of IgG antibody from Parkinsonism patients can cause substantia nigra 
destruction and Parkinson-like disease in rats.(Chen, Le et al. 1998) In a Brain paper, 
all Parkinsonism patients have IgG autoantibody recognizing dopaminergic 
neurons.(Orr, Rowe et al. 2005) In addition, Fc gamma receptors are up-regulated in 
lymphocytes and microglia of Parkinson disease patients. In an Experimental 
Neurology paper, injection of autoreactive IgG antibody isolated from Parkinsonism 
patients can also cause substantia nigra destruction in mice.(He, Le et al. 2002) In a 
paper from Journal of Neuroinflammation, serum antibodies from Parkinsonism 
patients can react with neuron membrane of mice dopaminergic cell line.(Huber, 
Mondal et al. 2006) In the presence of microglia, the serum antibodies can also 
suppress the production of dopamine from the mice dopaminergic cell line. In a JCI 
paper, CD4 T cell infiltration is found in postmortem Parkinson disease brain tissue 
and is related to neurodegeneration.(Brochard, Combadiere et al. 2009) In another 
paper of Journal of Neuroinflammation, complement activation is noted at 
substantia nigra isolated from expired Parkinsonian patients compared to normal 
control.(Loeffler, Camp et al. 2006) In a review paper, elevated autoantibodies and 
complements are found in serum and CSF of Parkinsonians. In addition, anti-alpha 
synuclein autoantibody is noted in familial Parkinsonism patients. Cytokine IL-1, TNF, 
and IL-6 are also increased in the serum, CSF, and substantia nigra of Parkinson 
disease patients. CD4 T cells are also increased in serum of Parkinson disease 
patients. In Parkinsonism’s substantia nigra, up-regulation of TH17 effector molecule 
iNOS and cycloxygenase are found.(Gatto, Carreras et al. 1996) As for the second 
criteria, autoreactive CD4 T cell infiltration is found in brain of mice Parkinsonism 
model, and these CD4 T cells contribute to neurodegeneration. In rat Parkinsonism 
model, CD4(+)CD25(+) Treg cells have neuroprotective roles and TH17 cells are 
detrimental(Reynolds, Stone et al. 2010). In mice Parkinsonism model, 
overexpression of human alpha synuclein can lead to microglia activation and 
adaptive immune reaction.(Zhang, Wang et al. 2005) In a Brain paper, local and 
systemic IL-1 can exacerbate neurodegeneration and motor symptoms in animal 
models of Parkinsonism.(Pott Godoy, Tarelli et al. 2008) In a Brain Research paper, 
IL-1 elevation induced by MPTP cause neurodegeneration in MPTP Parkinsonism 
mice models.(Bian, Li et al. 2009) In a Glia paper, TH17 effector cells-neutrophil 
infiltration in substantia nigra causes Parkinsonism-like symptoms. In addition, mice 
deficient in TNF receptor are protected from Parkinsonism symptoms. Systemic and 
local injection of extracellular bacteria product LPS can produce neurodegeneration 
including Parkisonism symptoms.(Meredith, Sonsalla et al. 2008) Key TH9 (THαβ) 
cytokine IL-10 has protective role in rat model of Parkinsonism.(Johnston, Su et al. 
2008) It is worth noting that alpha synuclein knockout mice didn’t develop 
Parkinsonism after MPTP injection.(Dauer, Kholodilov et al. 2002) MPTP can cause 
alpha synuclein up-regulation and aggregation in substantia nigra.(Vila, Vukosavic et 
al. 2000) Thus, alpha synclein is the major mediator of MPTP induced Parkinsonism. 
Autoimmune against alpha synuclein is the most likely pathogenesis. As for criteria 3, 
there is association between Parkinson’s disease and HLA haplotypes.(Hamza, 
Zabetian et al. 2010; Nalls, Plagnol et al. 2011) Besides, polymorphisms of TH17 
related cytokines such as IL-1α, IL-1β, TNF-α, TNF receptor, IL-1 receptor antagonist, 
CD14 receptor, and IL-6 are related to the risk of Parkinson’s disease.(Wahner, 
Sinsheimer et al. 2007) Elevated serum or CSF key TH17 cytokine IL-1 and IL-6 is also 
associated with the increasing risk of Parkinson’s disease.(Blum-Degen, Muller et al. 
1995) Autoimmune seborrheic dermatitis is associated with the risk of Parkinsonism. 
Anti-inflammatory caffeine, NASID, or estrogen intakes have protective role for the 
Parkinson’s disease development.(Giraud, Caron et al. 2010) Fetal stem cell 
transplant is newly used for Parkinson’s disease treatment. However, graft rejection 
is noted and there is only short-term beneficial effect not long-term therapeutic 
effect for the fetal stem cell transplant.(Spencer, Robbins et al. 1992; Bjorklund, 
Dunnett et al. 2003; Bachoud-Levi, Gaura et al. 2006; Krystkowiak, Gaura et al. 2007) 
It is because there are still autoreactive immune cells attacking alpha synuclein 
positive neuron cells. Thus, the new transplant will still be rejected by the abnormal 
host immune system. These evidences all point out that idiopathic Parkinson’s 
disease is an autoimmune disorder.  
 
Parkinson’s disease is TH17 dominant autoimmune disorder against alpha synuclein. 
Current treatment strategies include dopamine supplement and fetal stem cell 
transplant. However, these therapeutic methods could not solve the underlying 
pathogenesis of Parkinson’s disease and stop the disease progression. We should use 
anti-inflammatory agents such as NSAID to treat. In addition, we need to develop 
new strategy to induce tolerance for alpha synuclein to stop Parkinson’s disease. I 
sincerely hope we can control this detrimental illness in the future.  
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Figure legends 
 
Figure 1. RMA express plot for selecting samples in normal healthy controls. 
1-A NUSE boxplot for normal control 
1-B RLE boxplot for normal control 
1-C RLE-NUSE multiplot for normal control 
1-D RLE-NUSE T2 plot for normal control 
 
Figure 2. RMA express plot for selecting samples in Parkinson’s disease patients. 
2-A NUSE boxplot for Parkinson’s disease patients 
2-B RLE boxplot for Parkinson’s disease patients 
2-C RLE-NUSE multiplot for Parkinson’s disease patients 
2-D RLE-NUSE T2 plot for Parkinson’s disease patients 
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Table 1. Heat shock protein and TH17-related gene up-regulation in substantia nigra 
of Parkinson’s disease patients 
Probeset Pvalue Arrow Fold Gene Description 
 Heat Shock 
       200666_s_at 0.046436 up 1.591286 DNAJB1 Hsp40B1 
  200799_at 0.016182 up 1.942031 HSPA1A heat shock 70kDa protein 1A 
200800_s_at 0.009898 up 2.568059 HSPA1A/B heat shock 70kDa protein 1A 1B 
200881_s_at 0.025109 up 1.5808 DNAJA1 Hsp40A1 
  201491_at 0.00584 up 1.565841 AHSA1 activator of heat shock 90kDa  
201841_s_at 0.041056 up 1.93935 HSPB1 heat shock 27kDa protein 1 
202581_at 0.008943 up 2.568776 HSPA1A/B heat shock 70kDa protein1A /1B 
206976_s_at 0.015495 up 1.938839 HSPH1 heat shock 105kDa/110kDa 1 
209015_s_at 0.001648 up 2.366288 DNAJB6 Hsp40B 6 
  210189_at 0.001899 up 1.692562 HSPA1L heat shock 70kDa protein 1-like 
221782_at 0.013571 down 1.539068 DNAJC10 Hsp40C10 
 227808_at 0.01902 down 1.660796 DNAJC15 Hsp40C15 
 230148_at 0.001627 up 1.813061 AHSA2 activator of heat shock 90kDa 
Toll-like 
       210166_at 0.014399 up 1.605882 TLR5 toll-like receptor 5 
 220146_at 0.046749 up 1.506414 TLR7 toll-like receptor 7 
 228234_at 0.002924 up 1.602183 TICAM2 toll-like receptor adaptor 2 
231779_at 0.014626 up 1.588289 IRAK2 IL-1 receptor-as kinase 2 
Transcription factor 
      M97935MBat 0.014721 down 1.52548 STAT1 signal transducer and activator1 
212501_at 0.047435 up 1.659838 CEBPB CCAAT/enhancer binding beta 
225527_at 0.00591 up 1.503377 CEBPG CCAAT/enhancerbinding gamma 
228188_at 0.012176 up 2.218706 FOSL2 FOS-like antigen 2 
 203574_at 0.043302 up 1.816873 NFIL3 nuclear factor, interleukin 3 
Caspase 
       206011_at 0.036084 up 1.51373 CASP1 caspase 1 
 209970_x_at 0.040759 up 1.542726 CASP1 caspase 1 
 Cytokine receptor 
      219255_x_at 0.012304 up 1.755705 IL17RB interleukin 17 receptor B 
224156_x_at 0.017114 up 1.627902 IL17RB interleukin 17 receptor B 
224361_s_at 0.020254 up 1.631049 IL17RB interleukin 17 receptor B 
206172_at 0.023187 down 1.60825 IL13RA2 interleukin 13 receptor, alpha 2 
236561_at 0.028704 up 1.605665 TGFBR1 TGF, beta receptor 1 
  
Table 2. TH17 related gene up-regulation in peripheral leukocytes of Parkinson’s 
disease patients 
Probe Set Fold  Arrow p-value Gene 
200052_s_at 1.188939 down 0.009691 ILF2 
200064_at 1.141238 down 0.015928 HSP90AB1 
200660_at 1.184608 up 0.025142 S100A11 
200704_at 1.161244 up 0.010052 LITAF 
200706_s_at 1.168248 up 0.043356 LITAF 
200986_at 1.17499 down 0.02649 SERPING1 
201244_s_at 1.164101 up 0.044455 RAF1 
201315_x_at 1.132939 up 0.030281 IFITM2 
201502_s_at 1.200774 up 0.017593 NFKBIA 
202201_at 1.200977 down 0.021401 BLVRB 
202270_at 1.28927 down 0.022318 GBP1 
202379_s_at 1.223381 up 0.016804 NKTR 
202388_at 1.256398 up 0.00215 RGS2 
202509_s_at 1.107859 up 0.013255 TNFAIP2 
202877_s_at 1.125594 up 0.037677 CD93 
203041_s_at 1.200253 up 0.01719 LAMP2 
203140_at 1.211998 up 0.013618 BCL6 
203430_at 1.122783 up 0.043456 HEBP2 
203561_at 1.141576 up 0.033892 FCGR2A 
203591_s_at 1.21527 up 0.003722 CSF3R 
203685_at 1.214759 down 0.01472 BCL2 
203778_at 1.104544 up 0.024774 MANBA 
203828_s_at 1.177826 down 0.036371 IL32 
203936_s_at 1.261711 up 0.026599 MMP9 
203973_s_at 1.265417 up 0.007709 CEBPD 
204007_at 1.119838 up 0.018176 FCGR3B 
204057_at 1.11098 down 0.03413 IRF8 
204466_s_at 1.481427 down 0.022285 SNCA 
204467_s_at 1.244787 down 0.049072 SNCA 
204489_s_at 1.11089 down 0.006604 CD44 
204581_at 1.121758 down 0.016833 CD22 
204666_s_at 1.105866 up 2.69E-04 RP5-1000E10.4 
205403_at 1.313192 up 0.002585 IL1R2 
205456_at 1.104177 down 0.0124 CD3E 
206420_at 1.246161 up 0.009528 IGSF6 
207008_at 1.262777 up 0.010445 IL8RB 
207094_at 1.125419 up 0.023716 IL8RA 
207104_x_at 1.10934 up 0.036019 LILRB1 
207314_x_at 1.115032 down 0.044444 KIR3DL2 
207536_s_at 1.121413 up 0.003446 TNFRSF9 
207643_s_at 1.168614 up 0.009971 TNFRSF1A 
207655_s_at 1.123825 down 0.048559 BLNK 
207697_x_at 1.153652 up 0.00905 LILRB2 
207827_x_at 1.351602 down 0.019893 SNCA 
207907_at 1.15163 up 2.80E-04 TNFSF14 
208405_s_at 1.251242 down 0.041759 CD164 
208485_x_at 1.117304 up 0.0214 CFLAR 
208540_x_at 1.108202 up 0.042068 S100A11/P 
208666_s_at 1.213137 down 1.26E-04 ST13 
208667_s_at 1.248621 down 3.96E-04 ST13 
208931_s_at 1.150311 down 0.019467 ILF3 
209189_at 1.164217 up 0.021235 FOS 
209508_x_at 1.140008 up 0.007207 CFLAR 
209671_x_at 1.184911 down 0.016073 TRA@ /// TRAC 
209723_at 1.28675 down 0.007788 SERPINB9 
209939_x_at 1.17078 up 0.009053 CFLAR 
210031_at 1.174872 down 0.027308 CD247 
210042_s_at 1.265922 up 0.048335 CTSZ 
210225_x_at 1.137269 up 0.003548 LILRB3 
210514_x_at 1.105079 up 0.040499 HLA-G 
210563_x_at 1.152512 up 0.007233 CFLAR 
210564_x_at 1.141197 up 0.011338 CFLAR 
210754_s_at 1.254778 up 0.018888 LYN 
210776_x_at 1.100981 down 0.009593 TCF3 
210784_x_at 1.20723 up 7.90E-04 LILRA6 /// LILRB3 
210943_s_at 1.309776 up 0.003924 LYST 
210972_x_at 1.199937 down 0.030357 TRA@ 
211005_at 1.149716 down 0.009554 LAT /// SPNS1 
211133_x_at 1.118174 up 0.010374 LILRA6 /// LILRB3 
211135_x_at 1.184438 up 0.001229 LILRB3 
211163_s_at 1.210836 up 0.005458 TNFRSF10C 
211316_x_at 1.20165 up 0.003518 CFLAR 
211339_s_at 1.215744 down 0.025145 ITK 
211372_s_at 1.208659 up 0.009117 IL1R2 
211546_x_at 1.339729 down 0.017353 SNCA 
211862_x_at 1.13062 up 0.014222 CFLAR 
211902_x_at 1.185072 down 0.006675 TRA@ 
212414_s_at 1.224381 down 0.018298 N-PAC /// SEPT6 
213318_s_at 1.150105 down 0.031006 BAT3 
213894_at 1.100305 up 0.002152 THSD7A 
214359_s_at 1.19457 down 0.037662 HSP90AB1 
214486_x_at 1.186758 up 0.001419 CFLAR 
214574_x_at 1.107749 up 0.041912 LST1 
215338_s_at 1.139026 up 0.007906 NKTR 
215967_s_at 1.108165 down 0.012386 LY9 
216300_x_at 1.126279 up 0.002184 RARA 
217412_at 1.122067 down 0.016503 TRD@ 
217433_at 1.12529 up 0.00102 TACC1 
217550_at 1.114039 up 0.030685 ATF6 
217552_x_at 1.105204 up 0.047014 CR1 
217724_at 1.163798 down 0.039041 SERBP1 
217775_s_at 1.149285 down 0.003501 RDH11 
218450_at 1.16605 down 0.043368 HEBP1 
218831_s_at 1.131095 up 0.022043 FCGRT 
219528_s_at 1.187628 down 0.032716 BCL11B 
219667_s_at 1.197731 down 0.014477 BANK1 
220088_at 1.18788 up 0.040003 C5AR1 
220938_s_at 1.101576 up 8.66E-04 GMEB1 
221478_at 1.437751 down 0.006494 BNIP3L 
221571_at 1.120485 down 0.011251 TRAF3 
221602_s_at 1.161923 down 0.001686 FAIM3 
222218_s_at 1.143145 up 0.031853 PILRA 
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